BST1抗体;BST1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11609(BST1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P11609(BST1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The BST1 (Bone Marrow Stromal Cell Antigen 1) antibody targets the BST1 protein, a glycosylated cell surface enzyme also known as CD157. BST1 belongs to the ADP-ribosyl cyclase family and shares structural homology with CD38. playing roles in NAD metabolism, calcium signaling, and cell adhesion. Initially identified in bone marrow stromal cells, it is expressed in immune cells, endothelial cells, and certain cancer tissues. BST1 regulates immune responses, leukocyte migration, and hematopoietic stem cell interactions in the bone marrow niche.

Research links BST1 to autoimmune diseases, cancer progression, and neurodegenerative disorders. Genome-wide studies associate BST1 polymorphisms with Parkinson’s disease risk, suggesting its involvement in neuroinflammation. In oncology, BST1 overexpression in leukemia, myeloma, and solid tumors correlates with metastasis and immune evasion, making it a potential biomarker or therapeutic target.

BST1 antibodies are essential tools for detecting protein expression in techniques like flow cytometry, immunohistochemistry, and Western blot. They aid in studying BST1's functional roles in cell signaling, tumor microenvironments, and immune regulation. Therapeutic applications are emerging, with monoclonal antibodies explored for blocking BST1-mediated pathways in cancers or autoimmune conditions, akin to CD38-targeting therapies like daratumumab. However, its dual enzymatic and receptor-like activities complicate mechanistic understanding, necessitating further research to clarify its pathophysiological roles and therapeutic potential.